Holen Sie sich die Stockscreener-App
28.86
7.37%
1.98
Handel nachbörslich:
28.21
-0.65
-2.25%
Metsera Inc Aktie (MTSR) Neueste Nachrichten
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i’s Positive Phase 1 Results - MSN
Cantor Fitzgerald reiterates Metsera stock rating on strong MET-233i results - Investing.com Nigeria
Promising Results Of Amylin Analogs In Obesity: Metsera Case Review (NASDAQ:MTSR) - Seeking Alpha
Cantor Fitzgerald Predicts Metsera FY2026 Earnings - Defense World
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
RFK Axes CDC Vaccine Advisors; Metsera’s Weight Loss Win; FDA Supports CGT - BioSpace
Metsera to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewswire
Metsera Shows Rising Price Performance With Jump To 92 RS Rating - Investor's Business Daily
Metsera (NASDAQ:MTSR) Price Target Raised to $62.00 at Guggenheim - Defense World
Metsera (NASDAQ:MTSR) Shares Gap Up Following Analyst Upgrade - Defense World
Metsera stock extends gains on obesity drug data (MTSR:NASDAQ) - Seeking Alpha
Metsera’s obesity candidate ‘comparable to leading GLP-1-based medicines’ - The Pharma Letter
Metsera price target raised to $62 from $56 at Guggenheim - TipRanks
Metsera CEO to Present Obesity Drug Pipeline at Goldman Sachs Healthcare Conference | MTSR Stock News - Stock Titan
Metsera Hits New High As Obesity Pipeline Gains Weight - RTTNews
Metsera Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Metsera chasing best-in-class profile with amylin program - biocentury.com
Metsera reports promising Phase 1 trial results for obesity treatment By Investing.com - Investing.com South Africa
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i - GlobeNewswire
Metsera’s Amylin Analog Stars In Obesity Phase I - insights.citeline.com
Obesity treatment startup Metsera rises on positive trial results - Sherwood News
metsera reports positive phase 1 trial results for obesity drug - Investing.com Australia
Obesity Newcomer Metsera Enters The Ring With A Punch — And A Big Stock Jump - Investor's Business Daily
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes By Stocktwits - Investing.com India
Metsera rises as experimental weight-loss drug shows promise in small early-stage trial - MSN
Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News
Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data - Benzinga
Metsera obesity monotherapy data ‘looks competitive,’ says BofA - TipRanks
Metsera Stock Climbs On Positive Results From Early Stage Trial For Investigational Weight-Loss Drug: Retail Chatter Explodes - MSN
Metsera shares climb on early data for amylin-targeting obesity shot - BioPharma Dive
Warner Bros. Discovery, Metsera, eToro Group And Other Big Stocks Moving Higher On Monday - Benzinga
Metsera's Phase 1 Trial of MET-233i Shows Weight Reduction With no Severe Adverse Events - marketscreener.com
Metsera Shares Rise as Monthly Weight Loss Injection Shaves Over 8% Body Weight at 36 Weeks - BioSpace
Metsera’s drug shows potential in early clinical trial - statnews.com
metsera reports positive phase 1 trial results for obesity drug By Investing.com - Investing.com Canada
Metsera shares soar on positive amylin candidate trial results By Investing.com - Investing.com Nigeria
Metsera shares soar on positive amylin candidate trial results - Investing.com Australia
Metsera announces topline data from Phase 1 trial of MET-233i - TipRanks
Metsera, Inc. Reports Positive Phase 1 Trial Results - TipRanks
Obesity Startup Metsera Shares Rise on Early-Stage Trial Results - Bloomberg.com
Metsera reports promising Phase 1 trial results for obesity treatment - Investing.com
Metsera’s amylin drug shows early potential for substantial weight loss - statnews.com
Weight Loss Drug Shows 8.4% Reduction in Phase 1 Trial, Monthly Dosing Success | MTSR Stock News - Stock Titan
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association® - The Manila Times
Metsera to Present New Research Highlighting the Breadth - GlobeNewswire
Metsera to Present New Research Highlighting the Breadth and Momentum of its Next-Generation Obesity Portfolio at the 85th Scientific Sessions of the American Diabetes Association - TradingView
Next-Gen Monthly Obesity Drug Shows Promise: Metsera to Present Breakthrough Clinical Data at ADA 2025 - Stock Titan
Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership - insights.citeline.com
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):